Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Long intergenic non-protein coding RNA 1465 (LINC01465) is a member of the lincRNA subclass of long non-coding RNAs, which are defined as regulatory RNA transcripts longer than 200 nucleotides that do not overlap with coding genes[1][5]. LINC01465 is located on chromosome 12q14.1 and has been detected at high levels in specific epithelial ovarian cancer (EOC) cell lines, where it may influence cancer cell migration and survival[2][4]. Silencing LINC01465 in cancer models reduces migration and modifies drug response, suggesting a role in gene expression networks governing tumor cell behavior. While it is not a classical therapeutic target such as a receptor or enzyme, LINC01465 and related lincRNAs attract attention for their regulatory functions and as potential diagnostic or prognostic biomarkers, especially in oncology[1][2][3][5]. The precise molecular mechanisms and broader biological implications of LINC01465 remain under investigation.
Not established as a direct drug target; may mediate drug response or resistance by regulating gene networks influencing cell death or migration
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Long intergenic non-protein coding RNA 1465 (LINC01465).